• Personalis partnered with Link Medical Solutions to commercialize its NeXT Personal Dx minimal residual disease test in Great Britain.
• Link Medical will support rollout to expand access for clinicians and patients across England, Wales, and Scotland.
• The move follows UKCA marking for NeXT Personal Dx, enabling clinical use and supporting multinational biopharma trials spanning the UK and US.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607140600BIZWIRE_USPR_____20260714_BW263128) on July 14, 2026, and is solely responsible for the information contained therein.